Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Up 6.9% in March

Kazia Therapeutics Limited (NASDAQ:KZIA) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 259,500 shares, a growth of 6.9% from the March 15th total of 242,800 shares. Based on an average daily trading volume, of 838,400 shares, the short-interest ratio is presently 0.3 days.

Kazia Therapeutics Price Performance

Shares of NASDAQ:KZIA opened at $0.34 on Thursday. The company’s fifty day moving average price is $0.29 and its 200-day moving average price is $0.44. Kazia Therapeutics has a one year low of $0.19 and a one year high of $1.68.

Hedge Funds Weigh In On Kazia Therapeutics

Institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC bought a new position in shares of Kazia Therapeutics in the 4th quarter worth $45,000. Morgan Stanley grew its holdings in shares of Kazia Therapeutics by 25.9% during the 4th quarter. Morgan Stanley now owns 257,341 shares of the company’s stock valued at $158,000 after purchasing an additional 52,891 shares during the last quarter. Platinum Investment Management Ltd. bought a new position in shares of Kazia Therapeutics during the 4th quarter valued at $801,000. Finally, Armistice Capital LLC bought a new position in shares of Kazia Therapeutics during the 4th quarter valued at $1,088,000. Institutional investors own 30.89% of the company’s stock.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.